This indigenously developed enhanced care technology is designed to continuously monitor and detect early signs of deterioration in a patient's condition
Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes
The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Subscribe To Our Newsletter & Stay Updated
